Bonothyrk (A-21, bone / parathyroid bioregulator)
Khavinson-tradition short peptide positioned as a bone-and-parathyroid tissue bioregulator.
At a glance
What it is: Khavinson-tradition short peptide positioned as a bone-and-parathyroid tissue bioregulator..
Primary research applications:
- Bone health support research (Khavinson framework)
- Parathyroid-axis discussion in originating-tradition contexts
Editorial summary: Bonothyrk is the bone-and-parathyroid entry in the Khavinson bioregulator family. Positioned as supporting calcium-homeostasis and bone-tissue function via the same tissue-specific framework. Same lineage-concentrated evidence pattern.
- Class / structure
- Short peptide within the Khavinson cytogen family
- Half-life
- Very short systemic half-life
- First described
- Khavinson group, post-2000
- Regulatory status
- Sold as a supplement; not FDA-approved
What is Bonothyrk?
Bonothyrk is a short peptide bioregulator marketed within the Khavinson framework as supporting bone-tissue and parathyroid function.
Discovery and development
Bonothyrk (sometimes designated A-21) is one of the bone-tissue-targeted entries in the Khavinson bioregulator framework. The framework proposes specificity for bone and parathyroid tissue based on the framework's tissue-selective signaling hypothesis.
Mechanism of action
Within the Khavinson framework, Bonothyrk is positioned as supporting calcium-homeostasis-related tissue function via tissue-specific signaling. The mechanistic specifics — particularly the proposed direct DNA / nuclear interactions of small peptides — remain controversial outside the originating lineage.[1]
Pharmacokinetics
As a Khavinson short peptide, plasma half-life is very short. The proposed mechanism is direct tissue-targeted signaling rather than sustained systemic exposure.
What the research shows
The peer-reviewed literature on Bonothyrk is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).
Claims and the evidence behind them
This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.
| Claim | What the evidence shows | Verdict |
|---|---|---|
| Selectively supports bone-tissue and parathyroid function | Khavinson framework hypothesis | Uncertain |
| Independent replication of bone-density effects | Limited | Uncertain |
| Should be considered an established osteoporosis option | Mainstream bone-health pharmacology has substantially stronger evidence | Unsupported |
Reported user experiences
How the research describes administration
Oral capsules in cyclic regimens within the broader Khavinson product line.
Editorial note
Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness — these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.
Safety considerations and open questions
The takeaway
Bonothyrk is the bone-tissue arm of the Khavinson bioregulator framework. Its role in user communities is as part of cyclic Khavinson-bioregulator regimens for general aging support. For specific osteoporosis or bone-health concerns, the mainstream pharmacopeia (especially teriparatide as a peptide-class option, plus bisphosphonates and other approved agents) sits on a different evidence tier entirely.
Frequently asked questions
How does Bonothyrk compare to teriparatide for bone health?
Teriparatide (Forteo) is FDA-approved for osteoporosis with a Phase 3 fracture-prevention trial behind it. Bonothyrk sits in the Khavinson supplement-tradition framework. The two are not at comparable evidence tiers and address different patient contexts.
References
- Khavinson VK. Peptides and ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11-144. https://pubmed.ncbi.nlm.nih.gov/12422308/
- Khavinson VK, Linkova NS. Peptide bioregulators: a new class of geroprotectors. Adv Gerontol. 2020;10:34-45. https://pubmed.ncbi.nlm.nih.gov/?term=khavinson+bone